Puma Biotechnology | PBYI - Net Income


Puma Biotechnology reported $20.32M in Net Income for its fiscal quarter ending in September of 2024.





Net Income Change Date
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Amgen USD 1.82B 486M Mar/2026
Biogen USD 319.5M 368.4M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Daiichi Sankyo JPY 86.63B 41.32B Dec/2025
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
Exelixis USD 210.47M 34.06M Mar/2026
Gilead Sciences USD 2.02B 162M Mar/2026
Glaxosmithkline GBP 846.06M 1.87B Dec/2025
Incyte USD 303.33M 4.05M Mar/2026
MacroGenics USD -14.16M 30.98M Dec/2025
Moderna USD -1.34B 517M Mar/2026
Novartis USD 3.16B 747M Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Takeda JPY -24.32B 127.96B Mar/2026
TG Therapeutics USD 19.78M 3.26M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026